TG Therapeutics Inc (NASDAQ:TGTX) was up 7.1% during trading on Monday . The stock traded as high as $4.53 and last traded at $4.52. Approximately 1,772,076 shares changed hands during mid-day trading, an increase of 25% from the average daily volume of 1,423,353 shares. The stock had previously closed at $4.22.
Several equities research analysts have recently commented on TGTX shares. B. Riley assumed coverage on shares of TG Therapeutics in a research note on Tuesday, January 8th. They issued a “buy” rating and a $10.00 target price on the stock. HC Wainwright restated a “buy” rating on shares of TG Therapeutics in a research report on Tuesday, January 22nd. Zacks Investment Research upgraded shares of TG Therapeutics from a “hold” rating to a “buy” rating and set a $5.75 price target on the stock in a research report on Friday, November 16th. Jefferies Financial Group restated a “buy” rating and issued a $8.00 price target on shares of TG Therapeutics in a research report on Wednesday, February 6th. Finally, BidaskClub upgraded shares of TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, January 9th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the stock. TG Therapeutics has an average rating of “Buy” and a consensus price target of $13.58.
The company has a market capitalization of $350.67 million, a P/E ratio of -2.37 and a beta of 2.07.
In related news, CFO Sean A. Power sold 37,275 shares of the company’s stock in a transaction dated Wednesday, January 2nd. The shares were sold at an average price of $4.13, for a total transaction of $153,945.75. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 15.10% of the stock is owned by corporate insiders.
A number of large investors have recently bought and sold shares of the business. BlackRock Inc. lifted its holdings in TG Therapeutics by 2.2% during the 4th quarter. BlackRock Inc. now owns 4,519,331 shares of the biopharmaceutical company’s stock worth $18,529,000 after buying an additional 98,479 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of TG Therapeutics by 9.6% during the third quarter. Vanguard Group Inc. now owns 3,058,080 shares of the biopharmaceutical company’s stock valued at $17,125,000 after acquiring an additional 268,483 shares during the period. Vanguard Group Inc lifted its stake in shares of TG Therapeutics by 9.6% during the third quarter. Vanguard Group Inc now owns 3,058,080 shares of the biopharmaceutical company’s stock valued at $17,125,000 after acquiring an additional 268,483 shares during the period. Highland Capital Management LP lifted its stake in shares of TG Therapeutics by 60.5% during the third quarter. Highland Capital Management LP now owns 753,151 shares of the biopharmaceutical company’s stock valued at $4,218,000 after acquiring an additional 283,910 shares during the period. Finally, Northern Trust Corp lifted its stake in shares of TG Therapeutics by 19.3% during the second quarter. Northern Trust Corp now owns 751,725 shares of the biopharmaceutical company’s stock valued at $9,885,000 after acquiring an additional 121,424 shares during the period. 57.47% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION WARNING: This story was originally posted by WKRB News and is owned by of WKRB News. If you are accessing this story on another site, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this story can be viewed at https://www.wkrb13.com/2019/02/12/tg-therapeutics-tgtx-trading-up-7-1.html.
About TG Therapeutics (NASDAQ:TGTX)
TG Therapeutics, Inc, a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory chronic lymphocytic leukemia.
Further Reading: What is the price-sales ratio?
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.